Becketts advises The Hydration Pharmaceuticals Company (ASX: HPC) on the sale of its non-US assets to Prestige Consumer Healthcare

The Hydration Pharmaceuticals Company Limited (HPC) is an ASX-listed consumer products company that markets and sells a range of liquid, tablet and powder hydration products under the ‘Hydralyte’ brand in North America. HPC listed on the ASX in December 2021.

On 2 October 2024, HPC announced the divestment of its non-United States business and assets to Prestige Consumer Healthcare Inc., the owner of the Hydralyte business in Australia.

The sale price of A$13.7 million allows for the full repayment of debt and provides HPC with new capital to drive sales and margin growth from continuing operations in the United States.

Becketts is pleased to have assisted HPC with its initial public offering in 2021, debt financing in 2022, equity capital raising in 2023 and now the divestment of its non-US assets.

The Becketts team who advised HPC on the transaction was led by Nick Golding (Partner), supported by Dan Prior (Consultant).